.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,955,058

« Back to Dashboard

Details for Patent: 5,955,058

Title: Stabilized medicinal aerosol solution formulations containing ipratropium bromide
Abstract:Stabilized medicinal aerosol solution formulations comprising medicaments that degrade or decompose by interaction with solvents or water, an HFC propellant, a cosolvent and an acid are described. Further, specific medicinal aerosol solution formulations comprising ipratropium bromide or fenoterol, ethyl alcohol, 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane, and either an inorganic acid or an organic acid are described. The acids are present in amounts sufficient to reduce the degradation of the medicaments to acceptable levels.
Inventor(s): Jager; Paul Donald (Waterbury, CT), Kontny; Mark James (New Milford, CT), Nagel; Jurgen Hubert (Ingelheim/Rhein, DE)
Assignee: Boehringer Ingelheim Pharmaceuticals, Inc. (Ridgefield, CT)
Filing Date:Apr 14, 1997
Application Number:08/843,180
Claims:1. An aerosol solution formulation comprising from 0.001% to about 10% wt/wt ipratropium bromide, a hydrofluorocarbon propellant, an organic cosolvent, and an inorganic acid.

2. An aerosol solution according to claim 1 wherein the propellent is 1,1,1,2-tetrafluoroethane.

3. An aerosol solution formulation according to claim 2 wherein the organic cosolvent is ethyl alcohol.

4. An aerosol solution formulation according to claim 3 wherein the ethyl alcohol is in the range of about 1.0 to 50.0% wght./wght. of the formulation.

5. An aerosol solution formulation according to claim 3 wherein the inorganic acid is selected from the group consisting of sulfuric acid, hydrochloric acid, nitric acid, and phosphoric acid.

6. An aerosol solution formulation according to claim 3 which contains water in an amount up to about 5.0% wght./wght.

7. An aerosol solution formulation according to claim 1 wherein the propellant is 1,1,1,2,3,3,3-heptafluoropropane.

8. An aerosol solution formulation according to claim 7 wherein the organic cosolvent is ethyl alcohol.

9. An aerosol solution formulation according to claim 8 wherein the ethyl alcohol is in the range of about 1.0 to 50.0% wght./wght. of the formulation.

10. An aerosol solution formulation according to claim 8 wherein the inorganic acid is selected from the group consisting of sulfuric acid, hydrochloric acid nitric acid, and phosphoric acid.

11. An aerosol solution formulation comprising 0.001% to about 10 wt % ipratropium bromide, a hydrofluorocarbon propellant, ethyl alcohol and an inorganic acid which is hydrochloric acid, nitric acid, sulfuric acid or phosphoric acid.

12. An aerosol solution formulation according to claim 11 wherein the HFC propellant is 1,1,1,2-tetrafluoroethane.

13. An aerosol solution formulation according to claim 12 wherein the ethyl alcohol is within the range of about 1.0 to 50.0% wght./wght.

14. An aerosol solution formulation according to claim 11 wherein the inorganic acid is within the range of about 0.00002 to 0.01 Normal.

15. An aerosol solution formulation according to claim 11 wherein the amount of ipratropium bromide is about 0.0187% wght./wght.

16. An aerosol solution formulation according to claim 11 wherein the amount of ipratropium bromide is about 0.0374% wght./wght.

17. An aerosol solution formulation according to claim 11 wherein the amount of ipratropium bromide is about 0.0748% wght./wght.

18. An aerosol solution formulation according to claim 11 wherein the propellant is 1,1,1,2,3,3,3-heptafluoropropane.

19. An aerosol solution formulation comprising 0.001% to 10% wt/wt ipratropium bromide, oxitropium bromide, albuterol, metaproterenol, tiotropium bromide or fenoterol, a hydrofluorocarbon propellant, a cosolvent and an inorganic acid which is hydrochloric acid, nitric acid, sulfuric acid or phosphoric acid.

20. An aerosol solution formulation according to claim 19 wherein the propellant is 1,1,1,2-tetrafluoroethane.

21. An aerosol solution formulation according to claim 20 wherein the cosolvent is ethyl alcohol.

22. An aerosol solution formulation according to claim 19 wherein fenoterol is present in an amount of about 0.192% wght./wght.

23. An aerosol solution formulation according to claim 19 wherein the propellant is 1,1,1,2,3,3,3-heptafluoropropane.

24. An aerosol solution formulation according to claim 19 wherein the cosolvent is ethyl alcohol.

25. A method for stabilizing an aerosol solution formulation wherein the aerosol solution formulation comprises 0.001% to 10% wt/wt ipratropium bromide, 1,1,1,2-tetrafluoroethane and a cosolvent, and wherein the method comprises adding an inorganic acid to the aerosol solution formulation.

26. A method for stabilizing an aerosol solution formulation wherein the aerosol solution formulation comprises 0.001% to 10% wt/wt ipratropium bromide 1,1,1,2-tetrafluoroethane and a cosolvent, and wherein the method comprises adding an inorganic acid to the aerosol solution formulation.

27. The method according to claim 25 wherein the inorganic acid is hydrochloric acid, nitric acid, sulfuric acid, or phosphoric acid.

28. The method according to claim 26 wherein the inorganic acid is hydrochloric acid, nitric acid, sulfuric acid, or phosphoric acid.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc